15 Aug 2016
Change of Nominated Adviser

London, UK – 15 August 2016: Ergomed plc (LSE: ERGO) (‘Ergomed’ or ‘the Company’), a profitable UK-based group dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, announces that it has appointed Numis Securities Limited (“Numis”) as its Nominated Adviser with immediate effect. Stifel Nicolaus Europe Limited remain joint-broker to the Company alongside Numis.

 

Enquiries:

Ergomed plc                                                                          Tel: +44 (0) 1483 503205

Miroslav Reljanovic (Chief Executive Officer)

Stephen Stamp (Chief Financial Officer)

 

Numis Securities Limited                                                    Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Joint Broker)

 

Stifel Nicolaus Europe Limited                                           Tel: +44 (0) 20 7710 7600

Jonathan Senior (Joint Broker)

 

FTI Consulting                                                                      Tel: +44 (0) 20 3727 1000

Simon Conway / Mo Noonan / Natalie Garland-Collins

About Ergomed

Ergomed plc is a profitable UK-based business providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 50 countries.

Ergomed provides clinical development, trial management and pharmacovigilance services to over 100 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.

Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.

As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development. Lastly, Ergomed recently acquired a pipeline of proprietary development products for haemostasis in surgical settings. For further information, visit: http://ergomedplc.com.